Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080009 | 0.81 | NPC1 (0.61) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9125515 | 0.81 | LTA4H (0.61) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9746554 | 0.81 | LTA4H (0.61) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL488757 | 0.81 | LTA4H (0.61) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6079375 | 0.81 | LTA4H (0.61) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18171756 | 0.80 | ALDH1A1 (0.66) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL4810956 | 0.80 | ALDH1A1 (0.57) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL488392 | 0.78 | IDO1 (0.46) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL31061114 | 0.78 | LTA4H (0.58) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6080116 | 0.78 | LTA4H (0.58) | LTA4HMAPK14NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603570-B9 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1603570-B1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-5409943-A | [(alkoxy)pyridinyl]amine compounds which are useful in the treatment of gastrointestinal disorders | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1995-04-25 | — | — | US | disclosed |
| EP-0625143-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015055-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1993-08-05 | — | — | WO | disclosed |
| EP-0204285-B1 | IMIDAZOHETEROCYCLIC COMPOUNDS PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-4725601-A | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | LTA4H 4259/4885MAPK14 210/4885NPC1 4515/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | LTA4H 3789/4885MAPK14 152/4885NPC1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.